Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

Not yet recruiting

Phase 1/2 Results N/A

Trial Description

Administration of cell-free exosomes derived from mesenchymal stem cell (MSCs) can be sufficient to exert therapeutic effects of intact MSCs after brain injury. In this study we aim to assay the administration of MSC derived exosome enriched by miR-124 on improvemen of disability of patients with acute ischemic stroke

Detailed Description

Exosomes derived from multipotent mesenchymal stromal cells (MSCs) promote neurovascular remodeling and functional recovery after stroke. Animal study has shown that Exosome treatment markedly increased the number of newly formed doublecortin (a marker of neuroblasts) and von Willebrand factor (a marker of endothelial cells) cells. Based on previous literature, intravenous administration of MSC-generated exosomes post stroke improves functional recovery and enhances neurite remodeling, neurogenesis, and angiogenesis and represents a novel treatment for stroke. Also some studies have presented which miR-124-Loaded Exosomes ameliorate the brain Injury by promoting neurogenesis. So in present research we aim to assess improving of patients with acute ischemic stroke who received MSC derived exosome enriched by miR-124

Conditions

Interventions

  • Exosome Biological
    Intervention Desc: allogenic mesenchymal stem cells derived exosome enriched by miR-124
    ARM 1: Kind: Experimental
    Label: exosome or vesicle
    Description: CVA patients who have disability, will receive 200 microgram total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis

Outcomes

Type Measure Time Frame Safety Issue
Primary Incidence of Treatment-Emergent Adverse Events 12 months
Secondary measurement of Modified Ranking Scale (MRS) 12 months
Secondary measurement of Modified Ranking Scale 12 months

Sponsors